AALGO BREATHS I SEBI RA
@amit.bhattacharjee.5088
Kolkata
3+ Years of experience
SEBI Registration INH000019886Amit Bhattacharjee SEBI Registered Research Analyst | BSE Enlisted Founder – AALGO BREATHS (Reg. No. INH000019886 | BSE Code: 6508) 📈 Decoding Markets. Delivering Clarity. I’m Amit Bhattacharjee – a SEBI Registered Research Analyst and the mind behind AALGO BREATHS, where analysis meets intuition. With a background ... Read more
Trade Ideas
542
Opinions
956
Followers
117k
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 39 mins ago
Syngene International Limited Latest Updates
SYNGENE
Q1 FY27 Financial Results & Net Loss
On July 29, 2026, Syngene International reported its financial results for the first quarter ended June 30, 2026 (Q1 FY27). Revenue from operations declined 15.8% year-on-year to ₹736 crore (down from ₹874.5 crore in Q1 FY26). Lower operating leverage, biologics demand adjustments, and an exceptional charge of ₹13.5 crore for employee termination benefits led to a consolidated net loss of ₹9.00 crore, compared to a net profit of ₹86.70 crore in the year-ago period.
Executive Leadership Transition
Effective July 1, 2026, Mr. Siddharth Mittal officially took charge as the Managing Director and Chief Executive Officer (MD & CEO) of Syngene International, succeeding Peter Bains following a planned leadership transition. Alongside the CEO transition, the company appointed new commercial leadership to accelerate client outreach across the US and European contract development and manufacturing (CDMO) markets.
Balance Sheet Liquidity & Cash ReservesDespite operating headwinds in Q1 FY27, Syngene maintained a conservative capital structure with a net cash reserve of ₹1,541 crore. The strong balance sheet provides financial headroom as the company manages operating expenses and continues commercial integration for its US Bayview facility and biologics development infrastructure.
Technology & Research Collaborations
Syngene expanded its proprietary ***** drug discovery platform, deploying gigascale virtual screening capabilities to enhance early-stage hit-finding for global pharmaceutical clients. In clinical development, the company signed a strategic Memorandum of Understanding (MoU) with the Translational Health Science and Technology Institute (BRIC-THSTI) to collaborate on early and late-phase clinical trials and translational research. shared an insight ⚡️ 23 hours ago
Motisons Jewellers Limited Latest Updates
MOTISONS
Q1 FY27 Financial Results & Revenue Growth
On August 12, 2026, Motisons Jewellers released its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27). Total income grew 23.31% year-on-year to ₹107.34 crore (₹10,733.68 lakh), up from ₹87.05 crore in Q1 FY26, driven by sustained retail demand across its regional jewelry showroom network.
₹150 Crore Fundraise via Qualified Institutions Placement (QIP)
At its Board meeting held on August 12, 2026, the company approved the issuance and allotment of 13,57,46,600 equity shares (face value ₹1 each) at an issue price of ₹11.05 per share to eligible qualified institutional buyers. The QIP successfully raised ₹150 crore to strengthen working capital, expand showroom presence, and bolster precious metals inventory.
Monitoring Statement on Fund Utilization
In its regulatory submission to BSE and NSE on August 12, 2026, the company confirmed zero deviation or variation in the utilization of ₹320 crore in funds previously raised through public/preferential capital issuances, in compliance with SEBI LODR regulations.
Capital Restructuring & Preference Share Redemption
In corporate capital updates, the company concluded its earlier warrant conversion cycle, where 17.30 lakh warrants were converted into equity, while 82.70 lakh unexercised warrants lapsed, leading to a forfeiture of ₹35.15 crore. Additionally, the Board cleared the full redemption of 50,00,000 (50 lakh) 2.5% Non-Convertible Redeemable Preference Shares, optimizing the company's equity capital base. shared an insight ⚡️ 15th Aug
Minda Corporation Limited (Spark Minda) Latest Updates
MINDACORP
Record Q1 FY27 Financial Outperformance
On August 13, 2026, Minda Corporation reported its strongest-ever quarterly results for the first quarter ended June 30, 2026. Consolidated operational revenue jumped 33.2% year-on-year to ₹1,846.31 crore (up from ₹1,386 crore in Q1 FY26). Operating EBITDA rose 35.3% YoY to ₹211.63 crore, with margins expanding to 11.46%. Consolidated net profit (PAT attributable to owners) surged 216.9% YoY to ₹206.25 crore, aided by an exceptional gain of ₹106 crore (net of tax) arising from the consolidation of Minda VAST.
Consolidation of Minda VAST
Effective Q1 FY27, the company formally commenced the financial and operational consolidation of Minda VAST. The move expands Minda Corp’s vehicle-access systems footprint within the passenger vehicle segment, adding specialized product lines such as smart locksets, electronic latches, handles, immobilizers, passive keyless entry systems, and power-access solutions.
Strong Order Book Intake & EV Share
During Q1 FY27, Minda Corporation secured fresh lifetime orders aggregating ₹2,500 crore across product divisions. Electric vehicles (EVs) accounted for more than 15% of the new order pipeline, driven by new platform wins in wiring harnesses, sensor clusters, and smart connectivity modules.
Strategic Investments in Group Entities & R&D
During the quarter, Minda Corp deployed ₹63 crore in equity investments across three group entities—Spark Minda Green Mobility Systems, Minda HCMF Technologies, and Spark Minda–Toyodenso India—to fund production capacity additions and advanced electronics R&D. The company also filed 7 new technology patents during Q1 FY27, bringing its cumulative intellectual property portfolio to over 335 patents.FAQ's
What are the top stock recommendations by AALGO BREATHS I SEBI RA?
AALGO BREATHS I SEBI RA regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Astral Ltd (Bullish), Tbo Tek Ltd (Bullish), SYNGENE, MOTISONS and MINDACORP. Explore AALGO BREATHS I SEBI RA's complete list of posts and trade views on their StockGro profile.
How can I follow AALGO BREATHS I SEBI RA's latest investment insights?
You can follow AALGO BREATHS I SEBI RA's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is AALGO BREATHS I SEBI RA's investment strategy?
AALGO BREATHS I SEBI RA follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has AALGO BREATHS I SEBI RA been a SEBI-registered Research Analyst (RA)?
AALGO BREATHS I SEBI RA has been a SEBI-registered Research Analyst and have 3+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see AALGO BREATHS I SEBI RA's past performance and stock picks?
You can check AALGO BREATHS I SEBI RA's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact AALGO BREATHS I SEBI RA for stock market advice?
For stock market guidance from AALGO BREATHS I SEBI RA, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is AALGO BREATHS I SEBI RA's track record in predicting market movements?
AALGO BREATHS I SEBI RA has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for AALGO BREATHS I SEBI RA?
AALGO BREATHS I SEBI RA is a SEBI-registered Research Analyst with the SEBI Registration INH000019886. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro